Prelude Therapeutics snags $50m Series C

Wilmington, Delaware-based Prelude Therapeutics, a precision oncology company, has raised $50 million in Series C financing.

24 August 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles